Good Clinical Practice (GCP)
The international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials involving human subjects. E6(R3) restructures GCP around a set of overarching Principles plus Annex 1 (interventional trials), replacing the prescriptive E6(R2) checklist model with a risk-proportionate, quality-by-design approach that is media-agnostic across paper and electronic systems.
What this does not cover
stated in the document's own scope- Covers the conduct of clinical trials in humans; nonclinical laboratory safety studies are governed by Good Laboratory Practice (e.g. 21 CFR Part 58 / OECD GLP).
- Sets GCP for trial conduct, not the general design principles and critical-to-quality framing that precede it, which are ICH E8(R1).
- Defines GCP responsibilities and records, not the expedited safety-reporting definitions and timelines, which are ICH E2A.
- Is the human-subject clinical-quality standard, not a GMP guide for the investigational product’s manufacture.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH E6(R3) is the international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials that involve human participants. The R3 revision restructures Good Clinical Practice around a set of overarching Principles plus Annex 1 for interventional trials, replacing the more prescriptive checklist model of E6(R2) with a risk-proportionate, quality-by-design approach that is deliberately media-agnostic — written to apply equally to paper and to modern electronic and decentralised trial systems. It defines the responsibilities of sponsors, investigators, and institutional review boards/ethics committees, and the requirements for the protocol, informed consent, essential records, data governance, and trial oversight.
Scope & applicability
All interventional clinical trials of investigational products conducted to generate data submitted to regulatory authorities in ICH regions. Annex 1 applies to interventional trials; Annex 2 extends the principles to non-traditional and pragmatic designs.
Legal basis & how it acquires force
E6 is an ICH Efficacy guideline; the R3 revision reached Step 4 on 6 January 2025. An ICH guideline is not itself law; regions implement it. In the United States GCP obligations sit in FDA regulations (21 CFR Parts 50, 56, 312, and 812) with E6 adopted as guidance; in the EU, GCP is given force through the Clinical Trials Regulation and its detailed rules; and Japan implements GCP through MHLW ministerial ordinance. A sponsor complies with the regional instrument, and E6 is the harmonised standard those instruments reference.
Document structure
| Part | Covers |
|---|---|
| Principles of ICH GCP | The overarching principles — participant rights, safety, well-being, and reliable results — that govern all trials |
| Annex 1: Institutional Review Board / Independent Ethics Committee | Composition, functions, and responsibilities of the review body |
| Annex 1: Investigator | Investigator qualifications, resources, medical care, consent, and record responsibilities |
| Annex 1: Sponsor | Trial design, quality management, risk-based monitoring, data governance, and safety reporting |
| Annex 1: Data governance and essential records | Reliability of trial data across its lifecycle and the essential records to be retained |
| Protocol and investigator’s brochure | Required content of the trial protocol and the investigator’s brochure |
Key requirements
- Trials designed around pre-identified factors critical to quality, with proportionate controls
- Informed consent obtained and documented before any trial-specific procedure
- Sponsor oversight of all delegated activities, including vendors and decentralised elements
- ALCOA+ data governance maintained across the entire data lifecycle regardless of medium
- Validated computerised systems with audit trails for electronic trial records
- Safety information reported to sponsors, IRB/IECs, and authorities within required timelines
Implementation tips
- Rebuild monitoring plans around risk-based monitoring and critical-to-quality factors rather than blanket SDV
- Map every data flow (EDC, ePRO, wearables, labs) to an owner and an audit-trail review cadence
- Update vendor qualification and oversight SOPs — Annex 1 makes sponsors accountable for delegated tasks
- Confirm consent processes cover electronic and remote consent where used
Revision notes
Adopted at Step 4 on 6 January 2025, superseding E6(R2) (2016). Restructured into Principles + Annex 1, explicitly media-agnostic, with strengthened data governance and quality-by-design expectations. Annex 2 for non-traditional designs is expected to finalise later in 2025.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
E6(R3) is the operational core of the ICH Efficacy series, sitting downstream of E8(R1) — which frames the general principles and the identification of factors critical to quality that E6’s quality-by-design approach then implements. It connects to E2A and E2B for clinical safety reporting and to E3 for the clinical study report, and its risk-proportionate philosophy mirrors the quality-management thinking of the ICH quality guidelines.
ICH E6(R3): frequently asked questions
Quick answers to common questions about ICH E6(R3).
What is the current version of ICH GCP?
ICH E6(R3), which reached Step 4 on 6 January 2025, is the current revision. It restructures GCP into overarching Principles plus Annex 1 for interventional trials, superseding the E6(R2) checklist-style model.
How does E6(R3) differ from E6(R2)?
R3 replaces the prescriptive R2 model with a set of Principles and a risk-proportionate, quality-by-design approach, and it is written to be media-agnostic so it applies to electronic and decentralised trials as well as paper-based ones.
Is ICH E6(R3) legally binding?
Not by itself. GCP is enforced through regional law — FDA regulations (21 CFR 50/56/312/812) in the US, the Clinical Trials Regulation in the EU, and MHLW ordinance in Japan — with E6 adopted as the harmonised standard those instruments reference.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.